Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Pilatova, Katerina ^a   Greplova, Kristina ^a   Demlova, Regina ^a,c   Bencsikova, Beatrix ^a   Klement, Giannoula Lakka ^a,b   Zdrazilova Dubska, Lenka ^a,c  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Angiogenesis; Cancer; CTAP III; IL 8; Inflammation; PF 4; Platelet

Indexed keywords

ANGIOGENESIS INHIBITOR; BETA THROMBOGLOBULIN; CHEMOKINE; FLUOROURACIL; RECOMBINANT THROMBOCYTE FACTOR 4; THROMBOCYTE FACTOR 4;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; PROTEIN FUNCTION; REVIEW;

ANIMALS; BLOOD PLATELETS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PLATELET FACTOR 4;

EID: 84879198450     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-42     Document Type: Review

References (95)

1. Platelets actively sequester angiogenesis regulators. Klement GL, Yip TT, Cassiola F, Kukuchi L, Cervi D, Podust V, Italiano JE, Wheatley E, Abou-Slaybi A, Bender E, Almog N, Kieran MW, Folkman J, Blood 2009 130 2835 2842
2. Platelet-derived chemokines in vascular biology. Von Hundelshausen P, Petersen F, Brandt E, Thromb Haemost 2007 97 704 713 17479180
3. CXC chemokines in angiogenesis. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM, J Leukoc Biol 2000 68 1 8 10914483
4. Chemokine and inflammatory cytokine changes during chronic wound healing. Fivenson DP, Faria DT, Nickoloff BJ, Poverini PJ, Kunkel S, Burdick M, Strieter RM, Wound Repair Regen 1997 5 310 322 10.1046/j.1524-475X.1997.50405.x 16984441
5. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. Strieter RM, Polverini PJ, Kunkel SL, J Biol Chem 1995 270 27348 27357 10.1074/jbc.270.45.27348 7592998
6. Amino acid sequence of human platelet factor 4. Deuel TF, Keim PS, Farmer M, Heinrikson RL, Proc Natl Acad Sci USA 1977 74 2256 2258 10.1073/pnas.74.6. 2256 267922
7. Genes for beta-thromboglobulin and platelet factor 4 are closely linked and form part of a cluster of related genes on chromosome 4. Tunnaclife A, Majumdar S, Yan B, Poncz M, Blood 1992 79 2896 2900 1316786
8. New synthesis of a platelet-specific protein: platelet factor 4 synthesis in a megakaryocyte-enriched rabbit bone marrow culture system. Ryo R, Nakeff A, Huang SS, Ginsberg M, Deuel TF, J Cell Biol 1983 96 515 520 10.1083/jcb.96.2.515 6833369
9. Characterization of a chondroitin 4-sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4) released from human blood platelets. Barber AJ, Käser-Glanzmann R, Jakábová M, Luscher EF, Biochem Biophys Acta 1972 286 312 329 10.1016/0304-4165(72)90267-X 4267228
10. Normal ranges of angiogenesis regulatory proteins in human platelets. Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Fox L, Klement GL, Folkman J, Am J Hematol 2010 85 487 493 10.1002/ajh.21732 20575035
11. Platelet factor 4: production, structure, and physiologic and immunologic action. Zucker B, Katz R, Proc Soc Exp Biol Med 1991 198 693 702 10.3181/00379727-198-43309 1718005
12. Molecular pathways of platelet factor 4/CXCL4 signaling. Kaper B, Petersen F, Eur J Cell Biol 2011 90 521 526 10.1016/j.ejcb.2010.12.002 21295372
13. Studies of human plate alpha-granule release in vivo. Files JC, Malpass TW, Yee EK, Ritchie JL, Harker LA, Blood 1981 58 607 618 6266431
14. The role of platelet factor 4 in platelet aggregation induced by the antibodies implicated in heparin-induced thrombocytopenia. Gerotziafas GT, Elalamy I, Lecrubier C, Lebrazi J, Mirshahi M, Potevin F, Lecompte T, Samama MM, Blood Coagul Fibrinolysis 2001 12 511 520 10.1097/00001721-200110000-00002 11685038
15. Dansyl (5-dimethylaminonaphthalene-1-sulphonyl)-heparin binds antithrombin III and platelet factor 4 at separate sites. Piepkorn MW, Biochem J 1981 196 649 651 7317004
16. Inhibition of the activation of Hageman factor (factor XII) by platelet factor 4. Dumenco LL, Everson B, Culp LA, Ratnoff OD, J Lab Clin Med 1988 112 394 400 3045234
17. Calcium-binding sites of the thrombin-thrombomodulin-protein C complex: possible implications for the effect of platelet factor 4 on the activation of vitamin K-dependent coagulation factors. Yang L, Rezaie AR, Thromb Haemost 2007 97 899 906 17549291
18. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Slungaard A, Fernandez JA, Griffin JH, Key NS, Long JR, Piegors DJ, Lentz SR, Blood 2003 102 146 151 10.1182/blood-2002-11-3529 12609838
19. Negative regulation of human megakaryocytopoiesis by human platelet factor 4 (PF4) and connective tissue-activating peptide (CTAP-III). Han ZC, Bellucci S, Walz A, Baggiolini M, Caen JP, Int J Cell Cloning 1990 8 253 259 10.1002/stem.5530080409 2401804
20. Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Han ZC, Sensébe L, Abgrall JF, Brière J, Blood 1990 75 1234 1239 2310823
21. Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Lambert MP, Rauova L, Bailey M, Sola-Visner MC, Kowalska MA, Poncz M, Blood 2007 110 1153 1160 10.1182/blood-2007-01-067116 17495129
22. Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes. Lambert MP, Wang Y, Bdeir KH, Nguyen Y, Kowalska MA, Poncz M, Blood 2009 114 2290 2298 10.1182/blood-2009-04-216473 19605848
23. The role of platelet factor 4 in radiation-induced thrombocytopenia. Lambert MP, Xiao L, Nguyen Y, Kowalska MA, Poncz M, Int J Radiat Oncol Biol Phys 2011 80 1533 1540 10.1016/j.ijrobp.2011.03.039 21740995
24. New insights into the negative regulation of hematopoiesis by chemokine platelet factor 4 and related peptides. Lecomte-Raclet L, Alemany M, Sequeira-Le Grand A, Amiral J, Quentin G, Vissac AM, Caen JP, Han ZC, Blood 1998 91 2772 2780 9531587
25. Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. Dudek AZ, Nesmelova I, Mayo K, Verfaillie CM, Pitchford S, Slungaard A, Blood 2003 101 4687 4694 10.1182/blood-2002-08-2363 12586630
26. Structural and biological characteristics of connective tissue activating peptide (CTAP-III), a major human platelet-derived growth factor. Castor CW, Miller JW, Walz DA, Cell Biol 1983 80 765 769
27. Constitutive and regulated expression of platelet basic protein in human monocytes. El-Gedaily A, Schoedon G, Schneemann M, Schaffner A, J Leukoc Biol 2004 75 495 503 14673015
28. Leukocyte-derived growth factor links the PDGF and CXC chemokine families of peptides. Lida N, Haisa M, Igarashi A, Pencev D, Grotendorst GR, FASEB J 1996 10 1336 1345 8836048
29. Megakaryocyte maturation is associated with expression of the CXC chemokine connective tissue-activating peptide CTAP III. Deutsch V, Bitan M, Friedmann Y, Eldor A, Vlodavsky I, Br J Haematol 2000 111 1180 1189 10.1046/j.1365-2141.2000.02476.x 11167759
30. Protease action and generation of beta-thromboglobulin-like protein followed by platelet activation. Resmi KR, Krishnan LK, Thromb Res 2002 106 229 236 10.1016/S0049-3848(02)00135-4 12297130
31. Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G. Schiemann F, Grimm TA, Hoch J, Gross R, Lindner B, Petersen F, Bulfone-Paus S, Brandt E, Blood 2006 107 2234 2242 10.1182/blood-2005-06-2424 16317101
32. Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. Walz A, Baggioloni M, J Exp Med 1990 171 449 454 10.1084/jem.171.2.449 2406364
33. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. Walz A, Dewald B, von Tscharner V, Baggiolini M, J Exp Med 1989 170 1745 1750 10.1084/jem.170.5.1745 2681518
34. Connective tissue activation. XIV. Composition and actions of a human platelet autacoid mediator. Castor CW, Ritchie JC, Williams CH Jr, Scott ME, Whitney SL, Myers SL, Sloan TB, Anderson BE, Arthritis Rheum 1979 22 260 272 10.1002/art.1780220308 420716
35. Connective tissue activating peptide III. Induction of synthesis and secretion of plasminogen activator by synovial fibroblasts. Ragsdale CG, Castor CW, Roberts DJ, Swartz KH, Arthritis Rheum 1984 27 663 667 10.1002/art. 1780270609 6539601
36. The beta-thromboglobulins and platelet factor 4: blood platelet derived CXC chemokines with divergent roles in early neutrophil regulation. Brandt E, Petersen F, Ludwig A, Ehlert JE, Bock L, Flad HD, J Leukoc Biol 2000 67 471 478 10770278
37. Structure and bioactivity of recombinant human CTAP-III and NAP-2. Proudfoot AE, Peitsch MC, Power CA, Allet B, Mermod JJ, Bacon K, Wells TN, J Protein Chem 1997 16 37 49 10.1023/A:1026390811336 9055206
38. Regulation of glucose transporters by connective tissue activating peptide-III isoforms. Tai PK, Liao JF, Hossler PA, Castor CW, Carter-Su C, J Biol Chem 1992 267 19579 19586 1527075
39. Stimulation of cellular sphingomyelin import by the chemokine connective tissue-activating peptide III. Stoeckelhuber M, Dobner P, Baumgärtner P, Ehlert J, Brandt E, Mentele R, Adam D, Engelmann B, J Biol Chem 2000 275 37365 37372 10.1074/jbc.M003709200 10956644
40. CXC chemokines connective tissue activating peptide-III and neutrophil activating peptide-2 are heparin/heaparan sulfate-degrading enzymes. Hoogewerf AJ, Leone JW, Reardon IM, Howe WJ, Asa D, Heinrikson RL, Ledbetter SR, J Biol Chem 1995 7 3268 3277
41. Angiogenesis-a new target for future therapy. Pandya NM, Dhalla NS, Santani DD, Vascul Pharmacol 2006 44 265 274 10.1016/j.vph.2006.01.005 16545987
42. Antimetastatic effects associated with platelet reduction. Gasic GJ, Gasic TB, Stewart CC, Proc Natl Acad Sci USA 1968 61 46 52 10.1073/pnas.61.1.46 5246932
43. The role of tumor-induced platelet aggregation, platelet adhesion and adhesive proteins in tumor metastasis. Karpatkin S, Ambrogio C, Pearlstein E, Prog Clin Biol Res 1988 283 585 606 3211961
44. Involvement of platelets in tumour angiogenesis? Pinedo HM, Verheul HM, D'Amato RJ, Folkman J, Lancet 1998 352 1775 1777 10.1016/S0140-6736(98)05095-8 9848370
45. Contribution of platelets to tumour metastasis. Gay LJ, Felding-Habermann B, Nat Rev Cancer 2011 11 123 134 10.1038/nrc3004 21258396
46. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate α-granules and differentially released. Italiano JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL, Blood 2008 111 1227 1233 17962514
47. Platelet factor-4 modulates fibroblast growth factor 2 (FGF2) activity and inhibits FGF2 dimerization. Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A, Blood 1998 91 3289 3299 9558385
48. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. Gengrinowitch S, Greenberg SM, Cohen T, Gitay-Goren H, Rockwell P, Maione TE, Levi BZ, Neufeld G, J Biol Chem 1995 270 15059 15065 10.1074/jbc.270.25.15059 7797488
49. Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. Nesmelova IV, Sham Y, Dudek AZ, van Eijk LI, Wu G, Slungaard A, Mortari F, Griffioen AW, Mayo KH, J Biol Chem 2005 280 4948 4958 15531763
50. Chemokine antagonists that discriminate between interleukin-8 receptors. Selective blockers of CXCR2. Jones SA, Dewald B, Clark-Lewis I, Baggiolini M, J Biol Chem 1997 272 16166 16169 10.1074/jbc.272.26.16166 9195914
51. Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein. Ehlert JE, Ludwig A, Grimm GA, Lindner B, Flad HD, Brandt E, Blood 2000 96 2965 2972 11049972
52. IL-8 directly enhances endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. Li A, Dubey S, Varney ML, Dave BJ, Singh RK, J Immunol 2003 170 3369 3376 12626597
53. Increased invasion through basement membrane by CXCL7-transfected breast cells. Tang Z, Yu M, Miller F, Berk RS, Tromp G, Kosir MA, Am J Surg 2008 196 690 696 10.1016/j.amjsurg.2008.08.001 18954601
54. Connective tissue activation. XIII. Stimulation of sulfated glycosaminoglycans synthesis in human connective tissue cells by peptide mediators from lymphocytes and platelets. Castor CW, Whitney SL, J Lab Clin Med 1978 91 811 821 641404
55. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Hristov M, Zernecke A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A, Weber C, Circ Res 2007 100 590 597 10.1161/01.RES.0000259043.42571.68 17272812
56. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. Grupta SK, Singh JP, J Cell Biol 1994 127 1121 1127 10.1083/jcb.127.4.1121 7962072
57. Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo. Yang L, Du J, Hou J, Jiang H, Zou J, BMC Cancer 2011 11 261 10.1186/1471-2407-11-261
58. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Jouan V, Canron X, Alemany M, Caen JP, Quentin G, Plouet J, Bikfalvi A, Blood 1999 94 984 993 10419890
59. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ, Science 1990 247 77 79 10.1126/science.1688470 1688470
60. Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate. Chadderton NS, Stringer SE, Int J Biochem Cell Biol 2003 35 1052 1055 10.1016/S1357-2725(02)00299-6 12672474
61. Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic aktivity. Lozano RM, Redondo-Horcajo M, Jiménez MÁ Zilberberg L, Cuevas P, Bikfalvi A, Rico M, Giménez-Gallego G, J Biol Chem 2001 276 35723 35734 10.1074/jbc.M101565200 11423536
62. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P, J Exp Med 2003 197 1537 1549 10.1084/jem.20021897 12782716
63. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Struyf S, Sologni L, Burdick MD, Vandercappellen J, Gouwy M, Noppen S, Proost P, Opdenakker G, Parmentier M, Gerard C, Sozzani S, Strieter RM, Van Damme J, Blood 2011 117 480 488 10.1182/blood-2009-11-253591 20980681
64. Platelet factor 4/CXCL4-stimulated human monocytes induce apoptosis in endothelial cells by the release of oxygen radicals. Woller G, Brandt E, Mittelstädt J, Rybakowski C, Petersen F, J Leukoc Biol 2008 83 936 945 10.1189/jlb.0907592 18203873
65. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Vandercappellen J, Van Damme J, Struyf S, Cytokine Growth Factor Rev 2011 22 1 18 10.1016/j.cytogfr.2010.10.011 21111666
66. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE, J Natl Cancer Inst 1990 82 848 853 10.1093/jnci/82.10.848 1692094
67. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. Kolber DL, Knisely TL, Malone TE, J Natl Cancer Inst 1995 15 304 309
68. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA, Nat Med 1997 3 437 442 10.1038/nm0497-437 9095178
69. Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis. Yamaguchi K, Ogawa K, Katsube T, Shimao K, Konno S, Shimakawa T, Yoshimatsu K, Naritaka Y, Yagawa H, Hirose K, Anticancer Res 2005 25 847 852 15868918
70. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A, Cancer Metastasis Rev 2008 27 31 40 10.1007/s10555-007-9108-5 18087678
71. Chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. Petersen F, Bock LA, Flad HD, Brandt E, J Immunol 1998 161 4347 4355 9780212
72. Platelet factor 4-induced neutrophil-endothelial cell interaction: involvement of mechanisms and functional consequences different from those elicited by interleukin-8. Petersen F, Bock L, Flad HD, Brandt E, Blood 1999 94 4020 4028 10590045
73. Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents. Han ZC, Lu M, Li J, Defard M, Boval B, Schlegel N, Caen JP, Blood 1997 89 2328 2335 9116276
74. Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M, Proc Natl Acad Sci USA 1993 90 3574 3577 10.1073/pnas.90.8.3574 8475106
75. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. von Hundelshausen P, Koenen RR, Sack M, Mause SF, Adriaens W, Proudfoot AE, Blood 2005 105 924 930 15459010
76. Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients. Pervushina O, Scheuerer B, Reiling N, Behnke L, Schröder JM, Kasper B, Brandt E, J Immunol 2004 173 2060 2067 15265941
77. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Scheuerer B, Ernst M, Dürrbaum-Landmann I, Fleischer J, Grage-Griebenow E, Blood 2000 95 1158 1166 10666185
78. Platelet factor 4 in conjunction with IL-4 directs differentiation of human monocytes into specialized antigenpresenting cells. Fricke I, Mitchell D, Petersen F, Böhle A, Bulfone-Paus S, Brandau S, FASEB J 2004 18 1588 1590 15319366
79. Effect of platelet-activating factor and platelet factor 4 on eosinophil adhesion. Hayashi N, Chihara J, Kobayashi Y, Kakazu T, Kurachi D, Yamamoto T, Nakajima S, Int Arch Allergy Immunol 1994 104 Suppl 1 57 59 7950406
80. Stimulation of histamine release from human basophils by human platelet factor 4. Brindley LL, Sweet JM, Goetzl EJ, J Clin Incest 1983 72 1218 1223 10.1172/JCI111077
81. Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8. Marti F, Bertran E, Llucià M, Villén E, Peiró M, Garcia J, Rueda F, J Leukoc Biol 2002 72 590 597 12223528
82. Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. Fleischer J, Grage-Griebenow E, Kasper B, Heine H, Ernst M, Brandt E, Flad HD, Petersen F, J Immunol 2002 169 770 777 12097379
83. Neutrophil-activating protein-2- and interleukin-8-mediated angiogenesis. Powell JA Jr, Mousa SA, J Cell Biochem 2007 102 412 420 10.1002/jcb.21302 17352409
84. Increased microvascular permeability in vivo in response to intradermal injection of neutrophil-activating protein (NAP-2) in rabbit skin. Osselaer NV, Damme JV, Rampart M, Herman AG, Am J Pathol 1991 13 23 27
85. The amino-terminal residues in the crystal structure of connective tissue activating peptide-III (des10) block the ELR chemotactic sequence. Malkowski MG, Lazar JB, Johnson PH, Edwards BF, J Mol Biol 1997 226 367 380
86. Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma. Belman N, Bonnem EM, Harvey HA, Lipton A, Invest New Drugs 1996 14 387 389 9157074
87. A phase 1/2 study of recombinant plateler factor 4 (rPF4) in patients with AIDS related Kaposi's sarcoma (KS) [abstract]. Kahn J, Ruiz R, Kerschmann R, Berger T, Ma R, Coleman R, Alford BL, Proc Am Soc Clin Oncol 1993 12 50
88. Phase I/II study of intravenous (IV) recombinant platelet factor 4 (rPF4) in AIDS-related Kaposi's sarcoma (AIDS-KS) [abstract]. Northfelt DW, Robles R, Lang W, Wagner B, Kahn J, Bonnem E, Proc Am Soc Clin Oncol 1995 14 288
89. Phase I study of recombinant platelet factor 4 (rPF4) in patients with metastatic melanoma and renal cell carcinoma [abstract]. Hersh EM, Wiggins CE, Crook LI, Bonem EM, Proc Am Soc Clin Oncol 1995 14 488
90. Phase I-II study of localized injection of recombinant platelet factor 4 (rPF4) in patients (pts) with recurrent high-grade glioma [abstract]. Dinapoli RP, Buckner JC, Rydberg CH, Mullan BP, Davis DH, Proc Am Soc Clin Oncol 1995
91. Platelet-associated PF-4 as a biomarker of early tumor growth. Cervi D, Yip TT, Bhattacharya N, Podust VN, Peterson J, Abou-Slaybi A, Naumov GN, Bender E, Almog N, Italiano JE Jr, Folkman J, Klement GL, Blood 2008 111 1201 1207 17914028
92. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Connors S, Oenick M, D'Amato RJ, Klement GL, Folkman J, Angiogenesis 2012 15 265 273 10.1007/s10456-012-9259-z 22402885
93. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L, Kondra J, McWilliams A, Man SF, Lam S, J Clin Oncol 2009 27 2787 2792 10.1200/JCO.2008.19.4233 19414677
94. Elevated levels of CXC chemokine connective tissue activating peptide (CTAP)-III in lung cancer patients. Lee G, Gardner BK, Elashoff DA, Purcell CM, Sandha HS, Mao JT, Krysan K, Lee JM, Dubinett SM, Am J Transl Res 2011 3 226 233 21654877
95. Connective tissue activating peptide III expression disappears progressively with increased dysplasia in human cervical epithelium. Grisaru D, Vlodavsky I, Prus D, Levavi H, Lessing JB, Eldor A, Friedmann Y, Gynecol Oncol 2000 79 23 27 10.1006/gyno.2000.5915 11006025